These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 14596658)

  • 21. Investigating women's preference for sildenafil or tadalafil use by their partners with erectile dysfunction: the partners' preference study.
    Conaglen HM; Conaglen JV
    J Sex Med; 2008 May; 5(5):1198-1207. PubMed ID: 18312284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tadalafil, a further innovation in the treatment of sexual dysfunction.
    Pomerol JM; Rabasseda X
    Drugs Today (Barc); 2003 Feb; 39(2):103-13. PubMed ID: 12698205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phosphodiesterase 5 inhibitors for erectile dysfunction.
    Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
    Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors.
    Dresser MJ; Desai D; Gidwani S; Seftel AD; Modi NB
    Int J Impot Res; 2006; 18(1):104-10. PubMed ID: 16307008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regaining of morning erection and sexual confidence in patients with erectile dysfunction.
    Kim SC
    Asian J Androl; 2006 Nov; 8(6):703-8. PubMed ID: 16855764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
    Hatzichristou D; Haro JM; Martin-Morales A; von Keitz A; Riley A; Bertsch J; Belger M; Wolka AM; Beardsworth A;
    Int J Clin Pract; 2007 Nov; 61(11):1850-62. PubMed ID: 17850306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Tadalafil for erectile dysfunction: efficacy evaluation].
    Wang X
    Zhonghua Nan Ke Xue; 2009 Apr; 15(4):379-83. PubMed ID: 19472916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [ED patients and their female partners prefer tadalafil].
    Gong BS
    Zhonghua Nan Ke Xue; 2011 Jun; 17(6):571-5. PubMed ID: 21735661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tadalafil (Cialis) for erectile dysfunction.
    Noviasky JA; Masood A; Lo V
    Am Fam Physician; 2004 Jul; 70(2):359-60. PubMed ID: 15291094
    [No Abstract]   [Full Text] [Related]  

  • 30. Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction.
    Eardley I; Gentile V; Austoni E; Hackett G; Lembo D; Wang C; Beardsworth A
    BJU Int; 2004 Oct; 94(6):871-7. PubMed ID: 15476525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy.
    Washington SL; Shindel AW
    Drug Des Devel Ther; 2010 Sep; 4():159-71. PubMed ID: 20856843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tadalafil (Cialis) for men with erectile dysfunction.
    Eardley I; Cartledge J
    Int J Clin Pract; 2002 May; 56(4):300-4. PubMed ID: 12074215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized, double-blind, placebo-controlled, cross-over study to assess the efficacy of tadalafil (Cialis) in the treatment of erectile dysfunction following three-dimensional conformal external-beam radiotherapy for prostatic carcinoma.
    Incrocci L; Slagter C; Slob AK; Hop WC
    Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):439-44. PubMed ID: 16965992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: results of a multicenter, randomized, open-label, crossover study.
    Dean J; Hackett GI; Gentile V; Pirozzi-Farina F; Rosen RC; Zhao Y; Warner MR; Beardsworth A
    J Sex Med; 2006 Jul; 3(4):650-661. PubMed ID: 16839321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.
    Mulhall JP; McLaughlin TP; Harnett JP; Scott B; Burhani S; Russell D
    J Sex Med; 2005 Nov; 2(6):848-55. PubMed ID: 16422809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report.
    Liguori G; Trombetta C; De Giorgi G; Pomara G; Maio G; Vecchio D; Ocello G; Ollandini G; Bucci S; Belgrano E
    J Sex Med; 2009 Feb; 6(2):544-52. PubMed ID: 19138360
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy of tadalafil in improving sexual satisfaction and overall satisfaction in men with mild, moderate, and severe erectile dysfunction: a retrospective pooled analysis of data from randomized, placebo-controlled clinical trials.
    Rosen RC; Shabsigh R; Kuritzky L; Wang WC; Sides GD
    Curr Med Res Opin; 2005 Nov; 21(11):1701-9. PubMed ID: 16307689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of the efficacy and tolerability of tadalafil 10 mg and 20 mg in Japanese patients with severe erectile dysfunction.
    Marumo K; Imaoka T; Fujimoto K; Watts S; Stothard D; McGill J
    J Sex Med; 2007 May; 4(3):745-752. PubMed ID: 17087800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of medium and long-term tadalafil use in spinal cord patients with erectile dysfunction.
    Lombardi G; Macchiarella A; Cecconi F; Del Popolo G
    J Sex Med; 2009 Feb; 6(2):535-43. PubMed ID: 19138363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapy of ED: PDE-5 Inhibitors.
    Shabsigh R
    Endocrine; 2004; 23(2-3):135-41. PubMed ID: 15146092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.